ActoGeniX Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 11

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $60M

  • Investors
  • 1

ActoGeniX General Information

Description

Operator of a biopharmaceutical company intended to develop and commercialize a new generation of biological drugs. The company's versatile and proprietary technology platform develops products based on a delivery system comprising living non-pathogenic micro-organisms for the oral administration of biopharmaceuticals, and unmet needs in gastrointestinal, immunological, and metabolic diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Technologiepark 4
  • 9052 Ghent
  • Belgium
+32 09
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • Technologiepark 4
  • 9052 Ghent
  • Belgium
+32 09

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ActoGeniX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 23-Feb-2015 $60M Completed Clinical Trials - General
7. Early Stage VC (Series B) 18-Apr-2013 Completed Clinical Trials - General
6. Grant 01-Feb-2011 Completed Startup
5. Grant 20-Aug-2009 Completed Startup
4. Early Stage VC 24-Mar-2009 Completed Startup
3. Grant 01-Jul-2007 Completed Startup
2. Early Stage VC (Series A) 06-Feb-2007 $25.9M $25.9M Completed Startup
1. University Spin-Out 01-Jan-2006 Completed Startup
To view ActoGeniX’s complete valuation and funding history, request access »

ActoGeniX Patents

ActoGeniX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-1383897-A2 Self-containing lactococcus strain Active 03-May-2001
EP-1383897-B1 Self-containing lactococcus strain Inactive 03-May-2001
EP-1194554-A1 Delivery of trefoil peptides Active 05-Jul-1999
EP-1194554-B1 Delivery of trefoil peptides Inactive 05-Jul-1999 C07K14/575

ActoGeniX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ActoGeniX Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aescap Life Sciences Mutual Fund Minority
Baekeland Fonds II Corporation Minority
Biovest (Belgium) Venture Capital Minority
EQT Life Sciences Venture Capital Minority
Gimv PE/Buyout Minority
You’re viewing 5 of 9 investors. Get the full list »

ActoGeniX FAQs

  • When was ActoGeniX founded?

    ActoGeniX was founded in 2006.

  • Where is ActoGeniX headquartered?

    ActoGeniX is headquartered in Ghent, Belgium.

  • What is the size of ActoGeniX?

    ActoGeniX has 11 total employees.

  • What industry is ActoGeniX in?

    ActoGeniX’s primary industry is Drug Discovery.

  • Is ActoGeniX a private or public company?

    ActoGeniX is a Private company.

  • What is the current valuation of ActoGeniX?

    The current valuation of ActoGeniX is .

  • What is ActoGeniX’s current revenue?

    The current revenue for ActoGeniX is .

  • How much funding has ActoGeniX raised over time?

    ActoGeniX has raised $59.8M.

  • Who are ActoGeniX’s investors?

    Aescap Life Sciences, Baekeland Fonds II, Biovest (Belgium), EQT Life Sciences, and Gimv are 5 of 9 investors who have invested in ActoGeniX.

  • When was ActoGeniX acquired?

    ActoGeniX was acquired on 23-Feb-2015.

  • Who acquired ActoGeniX?

    ActoGeniX was acquired by Precigen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process